Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam And Silence Settle Over RNAi Patents

Executive Summary

Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.

You may also be interested in...



Alnylam Offering Value-Based Deals In EU For Breakthrough RNAi Drug Onpattro

Alnylam's president tells Scrip the RNAi pioneer is offering outcomes-based contracts for its first ever product to payers in the European Union following Onpattro's approval there in August. He also says payers "must pay for innovation."

Interview: Silence Therapeutics’ Chair On Why Keeping Quiet Has Done The Biotech No Favors

Silence Therapeutics’ executive chair, Annalisa Jenkins, talks to Scrip about why there’s more to the company than a court case.

Silence Seeks Share Of Alnylam RNAi Success In Legal Action

The UK firm believes its siRNA stabilisation chemistryis represented in several late-stage RNAi studies and that market leader Alnylam requires a license that could have a material impact on Silence's market capitalization.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel